Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOLR hits “milestone”

This article was originally published in The Tan Sheet

Executive Summary

Bellevue, Wash.-based firm SCOLR Pharma announces Sept. 26 that it has achieved a "milestone" in its development and license agreement with Wyeth Consumer Healthcare, which will result in a payment from Wyeth. SCOLR expects to report the payment as "research and development revenues" for the quarter ended Sept. 30. In the original December 2005 agreement, SCOLR granted Wyeth the worldwide rights to utilize SCOLR's patented Controlled Delivery Technology for potential use in an OTC formulations, according to the firm...
Advertisement

Related Content

SCOLR May File NDA For Ibuprofen Product Following Break With Wyeth

Topics

Advertisement
UsernamePublicRestriction

Register

PS099808

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel